Drugs / RGB-14-P
last change Nov 2023 re-read 2 minutes ago

RGB-14-P

Developed for
postmenopausal osteoporosis
Investigated by
Gedeon Richter Plc.

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05087030 Sep 2021 → Oct 2023 postmenopausal osteoporosis Gedeon Richter Plc. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RGB-14-P ClinicalTrials.gov intervention name — accepted as the source's own label NCT05087030
Route Subcutaneous subcutaneous (SC) injection of RGB-14-P” NCT05087030